MedWorm: Alopecia Universalis

A case of alopecia universalis with agminated lentiginosis and multiple café‐au‐lait macules: a synchronous coincidence?

International Journal of Dermatology — Thu, 22 Dec 2011 05:56:40 +0100

(Source: International Journal of Dermatology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Renbök phenomenon in a patient with alopecia areata universalis and psoriasis

The Journal of Dermatology — Tue, 13 Dec 2011 05:00:00 +0100

(Source: The Journal of Dermatology)

Tumor necrosis factor-alpha in patients with alopecia areata

Indian Journal of Dermatology — Fri, 04 Nov 2011 04:00:00 +0100

Conclusion : Our findings support the evidence that elevation of serum TNF-α is associated with AA. The exact role of serum TNF-α in AA should be additionally investigated in future studies. (Source: Indian Journal of Dermatology)

Remission of Alopecia Universalis Following Successful Clinical Islet Transplantation

American Journal of Transplantation — Thu, 22 Sep 2011 04:00:00 +0100

(Source: American Journal of Transplantation)

Utility of dermoscopy in alopecia areata

Indian Journal of Dermatology — Sat, 10 Sep 2011 04:00:00 +0100

Conclusions: The most common dermoscopic finding of AA in our study was yellow dots, followed by black dots, broken hairs, short vellus hair and tapering hairs. Dermoscopic findings were not affected by the type of AA or the severity of the disease. (Source: Indian Journal of Dermatology)

Tetanus vaccine: First report of alopecia universalis: case report

Reactions — Wed, 18 May 2011 17:09:57 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

[Alopecia areata during anti-TNF alpha therapy: Nine cases.]

Annales de Dermatologie et de Cenereologie — Sun, 01 May 2011 11:30:04 +0100

We present nine cases of alopecia areata (AA) developed in patients treated with TNF-α blocking agents. PATIENTS AND METHODS: Nine cases are described: five men and four women of mean age 39.2years (range: 29-54years). Two patients had a past history of alopecia areata. The anti-TNF given was adalimumab (Humira(®)) in eight cases and etanercept (Enbrel(®)) in one case. The time lapse to development of AA following introduction of the anti-TNF alpha agent was between six weeks and eight months (mean: 4.2months). There were five cases of patchy AA and four of AA universalis. Anti-TNF alpha treatment was stopped in all patients. Complete regrowth was seen in five patients. Two patients showed no improvement. In two patients, partial hair regrowth (<50%) was seen after systemic corticost...

Systemic treatment for alopecia areata

Dermatologic Therapy — Sat, 30 Apr 2011 23:00:00 +0100

ABSTRACTOf the world population, 1.7% is suffering from alopecia areata at some point in their lives. The exact etiology of this disease is still unknown, and the course of the disease is unpredictable. Effective treatments, especially for severe multifocal alopecia areata, alopecia areata totalis, and alopecia areata universalis, are lacking. The present article will discuss side effects and relapse rates of different systemic agents for treatment of severe and rapid progressive alopecia areata. (Source: Dermatologic Therapy)

Topical and intralesional therapies for alopecia areata

Dermatologic Therapy — Sat, 30 Apr 2011 23:00:00 +0100

This article will review the available topical and intralesional agents that are used in the treatment of alopecia areata and suggest a management approach based on the age of the patient and extent of the disease. (Source: Dermatologic Therapy)

Identification of a new mutation in the gene coding for hairless protein responsible for alopecia universalis: The importance of direct gene sequencing.

Dermatol Online J — Tue, 01 Feb 2011 06:15:03 +0100

Authors: Nucara S, Colao E, Mangone G, Baudi F, Fabiani F, Nocera D, Passafaro G, Longo T, Laria AE, Malatesta P, Amato R, Trapasso F, Perrotti N Mutations in the gene HR coding for the hairless protein are associated with atrichia with papular lesions (APL), an autosomal recessive form of alopecia universalis that is characterized by generalized scalp and body atrichia with papular lesions. We here describe a South Italian family of ancient Albanian heritage. The full phenotype with complete atrichia was expressed in 2 siblings, whereas the parents and one sister were unaffected. Direct sequencing of the gene coding for the hairless protein allowed the identification of a new mutation in exon 17. Consistent with the recessive inheritance of the disease, both the siblings were homozygo...

Infliximab: Alopecia areata universalis: case report

Reactions — Tue, 30 Nov 2010 07:20:09 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Hypertrichosis in alopecia universalis and complex regional pain syndrome

Neurology — Mon, 18 Oct 2010 00:00:00 +0100

(No abstract is available for this citation) (Source: Neurology)

Alopecia areata universalis during off-label treatment with Infliximab in a patient with BehÃ§et disease.

Dermatol Online J — Thu, 30 Sep 2010 16:35:04 +0100

We describe a case of alopecia areata universalis associated with infliximab treatment in a patient with BehÃ§et disease. This case suggests a complex and contradictory role of TNF-Î± in the pathogenesis of alopecia areata. PMID: 20875336 [PubMed - in process] (Source: Dermatol Online J)

[Treatment of alopecia areata with prednisone in a once-monthly oral pulse.]

Annales de Dermatologie et de Cenereologie — Sat, 31 Jul 2010 23:00:00 +0100

CONCLUSION: A once-monthly oral pulse of 300mg prednisone appears effective and safe. It can be recommended as first-line treatment for widespread AA. PMID: 20804894 [PubMed - as supplied by publisher] (Source: Annales de Dermatologie et de Cenereologie)

[Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis.]

Annales de Dermatologie et de Cenereologie — Sat, 31 Jul 2010 23:00:00 +0100

CONCLUSION: MTX alone or in combination with low doses of oral corticosteroids resulted in complete hair regrowth in about half of these patients presenting AA totalis or universalis. Lasting improvement required continuous treatment in most cases. PMID: 20804893 [PubMed - as supplied by publisher] (Source: Annales de Dermatologie et de Cenereologie)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Pigmented contact dermatitis due to therapeutic sensitizer as complication of contact immunotherapy in alopecia areata

The Journal of Dermatology — Sun, 13 Jun 2010 23:00:00 +0100

Pigmentary complication by contact immunotherapy (CI) for alopecia areata (AA) has been reported but its pathophysiology remains unknown. To characterize pigmentary complication by CI and its pathophysiology, we examined the incidence of hyperpigmentation in 186 consecutive patients treated with CI using diphenylcyclopropenone. From clinical data of AA totalis (AAT) or universalis (AAU) patients (n = 78), we studied the correlations between this complication and age, sex, atopic background, duration and treatment responsiveness, duration of CI, final concentration of diphenylcyclopropenone and administration of anti-histamines by [chi]2-test or Mann[ndash]Whitney U-test. Additionally, the histopathology of pigmentation was studied. As a result, 11 (5.91%) of the 186 patients had hyperpigme...

Renbok Phenomenon and Contact Sensitization in a Patient With Alopecia Universalis [Observation]

Archives of Dermatology — Mon, 19 Apr 2010 19:51:11 +0100

Conclusions This case represents a natural experiment in which 3 distinct but overlapping immune responses favored psoriasis or contact dermatitis over alopecia areata. The precise mechanism responsible for these effects remains unclear; however, based on recent reports, we speculate that cytokine cross-regulation plays a role in competition among these distinct immune responses. (Source: Archives of Dermatology)

Autoimmune polyglandular syndrome-3C in a child.

Dermatol Online J — Sat, 20 Mar 2010 01:42:03 +0100

We report a case of APS-3C in 12-year-old boy with generalized vitiligo, alopecia universalis, and Hashimoto thyroiditis that is the youngest of previous reported cases. PMID: 20233565 [PubMed - in process] (Source: Dermatol Online J)

Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis

Journal of the European Academy of Dermatology and Venereology — Thu, 17 Dec 2009 00:00:00 +0100

Conclusions Latanoprost may be an effective drug in the treatment of eyelash AA because it induces acceptable responses (total and moderate) in 45% of the patients. A formal, blinded prospective unilateral controlled study will permit further understanding about this promising therapeutic agent for eyelash AA. (Source: Journal of the European Academy of Dermatology and Venereology)

Alopecia in Epidermolysis Bullosa

Dermatologic Clinics — Tue, 01 Dec 2009 14:33:07 +0100

This article reviews the hair abnormalities reported in the different subtypes of EB. (Source: Dermatologic Clinics)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy

Clinical And Experimental Dermatology — Thu, 22 Oct 2009 23:00:00 +0100

Conclusions. Increased Th1 serum cytokines (IL-2, IL-12 and interferon-[gamma]) and IL-1ra levels are associated with AA regardless of disease severity or the presence of atopy. (Source: Clinical And Experimental Dermatology)

Satoyoshi syndrome with unusual skeletal abnormalities and parental consanguinity

American Journal of Medical Genetics Part A — Thu, 15 Oct 2009 23:00:00 +0100

We describe a 26-year-old Mexican woman, a product of consanguineous parents with clinical characteristics of SS. Our patient, also showed skeletal anomalies not previously reported that seems to be a coincidental finding. © 2009 Wiley-Liss, Inc. (Source: American Journal of Medical Genetics Part A)

Novel and recurrent mutations in the AIRE gene of autoimmune polyendocrinopathy syndrome type 1 (APS1) patients.

Clinical Genetics — Mon, 14 Sep 2009 23:00:00 +0100

This study describes seven Arab families, in which 18 patients had APS1. In addition to the cardinal features of APS1, some patients exhibited alopecia, diabetes mellitus, nephrocalcinosis and other phenotypes associated with APS1. DNA sequencing of the AIRE gene of patients from this study identified four novel and one recurrent mutation. These mutations likely result in loss of AIRE function in the patients. In addition, it was noted that the non-pathogenic c.834C> G mutation (rs1800520, encoding for p.Ser278Arg) occurs with high incidence in the AIRE gene of Arab individuals. Furthermore, this investigation demonstrates inflammation of the hair follicles in APS1 patients with alopecia universalis. We conclude that Arab APS1 patients carry novel and recurrent mutations in the AIRE gen...

Five-year experience in the treatment of alopecia areata with DPC

Journal of the European Academy of Dermatology and Venereology — Mon, 07 Sep 2009 23:00:00 +0100

Conclusion Diphencyprone is an effective and safe treatment of extensive AA. A long period of therapy is needed and will increase the percentage of responders especially in alopecia totalis and universalis. Maintenance therapy is recommended to reduce the risk of relapse. (Source: Journal of the European Academy of Dermatology and Venereology)

Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata

Journal of the American Academy of Dermatology — Sun, 16 Aug 2009 23:00:00 +0100

Conclusion: Topical bexarotene 1% application is well tolerated and possibly effective. A randomized placebo-controlled trial should be conducted. (Source: Journal of the American Academy of Dermatology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

History of atopy or autoimmunity increases risk of alopecia areata

Journal of the American Academy of Dermatology — Thu, 16 Jul 2009 23:00:00 +0100

Conclusion: This analysis revealed that a history of atopy and autoimmune disease was associated with an increased risk of AA and that the results were consistent for both the severe subtype of AA (ie, alopecia totalis and alopecia universalis) and the localized subtype (ie, AA persistent). (Source: Journal of the American Academy of Dermatology)

The lived experience of alopecia areata: a qualitative study.

Body Image — Sun, 31 May 2009 23:00:00 +0100

This study explored experiences of individuals living with alopecia areata (AA) and alopecia universalis (AU) and investigated their accounts of adjusting to, and coping with, such conditions. Whilst previous research has primarily focused on the adverse psychosocial impact of alopecia, this investigation used Interpretive Phenomenological Analysis to provide a more holistic perspective. Biographical interviews were undertaken with 12 participants (7 women; 5 men) diagnosed with alopecia for periods ranging between 2 and 49 years. Results revealed that strategies used by participants evolved over time and that there were clear gender differences. In the early stages, participants did not want to contemplate that their hair loss would be lasting and managed the condition via concealment. La...

ICD: Steroid-Sparing Treatment Shows Promise for Alopecia (CME/CE)

MedPage Today Dermatology — Fri, 29 May 2009 13:04:06 +0100

PRAGUE (MedPage Today) -- Methotrexate-based, steroid-sparing therapy has induced hair growth in more than 90% of patients with alopecia universalis, according to an ongoing clinical evaluation. (Source: MedPage Today Dermatology)

Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata

Archives of Dermatological Research — Fri, 20 Mar 2009 10:41:20 +0100

Abstract Alopecia areata (AA) is regarded as a tissue-specific autoimmune disease for which several therapies have been suggested to modify the immune reaction against HFs, such as contact immunotherapy, psoralen plus ultraviolet A (PUVA), corticosteroids, cyclosporine, minoxidil, and dithranol. However, severe type AA, such as alopecia totalis (AT) and alopecia universalis (AU), often show resistance against these therapies. We applied a combination therapy with oral corticosteroid and oral PUVA for intractable cases of AT and AU. These patients took 20 mg/day corticosteroid and were irradiated with UVA on the whole body 2 h after taking methoxsalen for 1 month. In all patients, the terminal hair on the whole scalp regrew after 2 months. Two patients h...

Adalimumab: Alopecia areata universalis: case report.

Reactions Weekly — Sun, 07 Dec 2008 08:49:36 +0100

Page: 4 (Source: Reactions Weekly)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Adalimumab: Alopecia areata universalis: case report

Reactions — Sun, 07 Dec 2008 08:20:55 +0100

(Source: Reactions)

Alopecia Areata Universalis during Treatment of Rheumatoid Arthritis with Anti-TNF-a Antibody (Adalimumab)

Dermatology — Tue, 14 Oct 2008 10:43:51 +0100

Dermatology 2008;217:380 (DOI:10.1159/000162180) (Source: Dermatology)

Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria.

Acta Derm Venereol A... — Wed, 20 Aug 2008 07:57:56 +0100

Authors: Yip L, Horev L, Sinclair R, Zlotogorski A Atrichia with papular lesions is a rare autosomal recessive condition characterized by complete irreversible hair loss during the first months of life and papules that appear during early childhood. Atrichia with papular lesions is frequently misdiagnosed as alopecia universalis, despite increasing reports of its prevalence and the presence of well-defined diagnostic criteria. Most cases of atrichia with papular lesions have been reported in consanguineous families residing in small geographical regions, but the increasing number of sporadic cases of unrelated individuals suggests that atrichia with papular lesions is more common than previously thought. Mutations in the human hairless gene on chromosome 8p12 have been implicated in th...

Alopecia universalis with twenty-nail dystrophy (trachyonychia).

Dermatol Online J — Fri, 18 Jul 2008 07:28:48 +0100

Authors: Chien P, Kovich OI A 43-year-old man presented with long-standing trachyonychia of all 20 nails, which worsened after the onset of alopecia universalis 18 months ago. Trachyonychia can be associated with alopecia universalis although the treatment strategies of both conditions differ. The principle of treating trachyonychia may involve regulating the differentiation of keratinocytes and/or reducing inflammation in the nail fold or nail matrix while treatment of alopecia universalis involves immunomodulation. PMID: 18627760 [PubMed - in process] (Source: Dermatol Online J)

Pernicious anemia in a patient with Type 1 diabetes mellitus and alopecia areata universalis

Journal of Diabetes and Its Complications — Wed, 09 Jul 2008 00:00:00 +0100

Abstract: A 27-year-old male, who had developed diabetes mellitus type 1 (DMT1) since the age of eighteen and alopecia areata universalis nine months later, attended the outpatient clinics complaining of general fatigue and shortness of breath. A Schilling test was indicative of pernicious anemia. Antigastric parietal cell (AGPA) and anti-intrinsic factor antibodies were positive, confirming diagnosis of pernicious anemia. Thyroid and Addison's disease were excluded. Gastroscopy revealed atrophic gastritis without any evidence of carcinoid tumors. The aim of this case, which, to our knowledge, is the first one to describe a correlation between diabetes mellitus Type 1 (DMT1), pernicious anaemia, and alopecia areata universalis, is to remind the clinician of the increased risk of pernicious...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cochrane review: Interventions for alopecia areata

NeLM Headline News — Tue, 22 Apr 2008 00:00:00 +0100

According to the findings of a systematic review conducted by the Cochrane Collaboration, few treatments for alopecia areata (AA) have been well evaluated in randomised, controlled trials. AA is a disorder where there is a loss of hair with no scarring to the affected area. It can affect the entire scalp (alopecia totalis) or cause loss of all body hair (alopecia universalis). Its cause is not yet fully understood, and although it can start at any age, it will most commonly develop before 20 years of age. Although in many cases it can be a self-limiting condition, the hair loss will often have a severe social and emotional impact. Current treatments used for AA include corticosteroids (topical, local injection, oral, injection); systemic immunosuppression (e.g. psoralens plus PUVA); ora...

Adalimumab: Alopecia universalis: case report

Reactions — Mon, 21 Apr 2008 07:38:40 +0100

(Source: Reactions)

Adalimumab: Alopecia universalis: case report.

Reactions Weekly — Sat, 19 Apr 2008 07:37:25 +0100

Page: 4 (Source: Reactions Weekly)

Alopecia areata progressing to totalis/universalis in non-insulin dependent diabetes mellitus (type II): Failure of dexamethasone-cyclophosphamide pulse therapy

Indian Journal of Dermatology, Venereology and Leprology — Wed, 02 Apr 2008 09:56:40 +0100

Sehgal Virendra N, Bhattacharya Sambit N, Sharma Sonal, Srivastava Govind, Aggarwal Ashok KIndian Journal of Dermatology, Venereology and Leprology 2008 74(2):171-173 (Source: Indian Journal of Dermatology, Venereology and Leprology)

The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis.

Archives of Iranian Medicine — Tue, 01 Jan 2008 05:00:00 +0100

The objective of this study was to evaluate the therapeutic and side effects of pulse-therapy with methylprednisolone combined with oral cyclosporine in severe alopecia areata, defined as alopecia totalis and universalis. Six patients with alopecia totalis and 12 patients with alopecia universalis were referred to our center. The patients were treated with monthly intravenous methylprednisolone in doses of 500 mg for three days and oral cyclosporine (2.5 mg/kg/day) for five to eight months. Responses were categorized as: "adequate" (i.e., hair regrowth on > or =70% of the affected area) and "inadequate" (i.e., hair regrowth on <70% of the affected area). Adequate response was observed in six (33%) patients: three with alopecia totalis and 3 with alopecia universalis. Responses were b...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Alopecia areata universalis in an infant

Tue, 30 Oct 2007 14:45:23 +0100

Conclusions Alopecia areata should be included in the differential diagnosis of generalized alopecia presenting at or shortly after birth. For purposes of genetic counseling and prognosis, it is crucial that a correct diagnosis be made. Content Type Journal ArticleCategory Case ReportsDOI 10.1007/BF02737867Authors Jo Anne LaRow, Albany Medical College A-81 Division of Dermatology and Dermatopathology 12208 Albany NY USAJudith Mysliborski, Capital District Dermatology 12208 Albany New YorkI. Paul Rappaport, Aesthetic Laser & Skin Care Center 12866 Saratoga Springs New YorkGuy A. Rouleau, Montreal General Hospital Centre for Research in Neurosciences H3G 1A4 Montréal CanadaJ. Andrew Carlson, Albany Medical College A-81 Division of Dermatology and Dermatopathology 12208 ...

Peginterferon-[alpha]-2b/ribavirin: Alopecia universalis: case report.

Reactions Weekly — Tue, 11 Sep 2007 01:05:08 +0100

Page: 23 (Source: Reactions Weekly)

Peginterferon--2b/ribavirin: Alopecia universalis: case report

Reactions — Sun, 09 Sep 2007 12:10:52 +0100

(Source: Reactions)

Reversible alopecia universalis secondary to PEG-interferon [alpha]-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.

European Journal of Gastroenterology & Hepatology — Wed, 15 Aug 2007 00:55:31 +0100

Page: 817DOI: 10.1097/MEG.0b013e32818b27e5Authors: Kartal, Elif Doyuk; Alpat, Saygn Nayman [latin dotless i]; Ozgunes, Ilhan; Usluer, Gaye (Source: European Journal of Gastroenterology & Hepatology)

Alopecia areata universalis and acute lymphoblastic leukemia

American Journal of Hematology — Fri, 06 Jul 2007 04:00:00 +0100

No abstract. (Source: American Journal of Hematology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Effect of homeopathic treatment of 60 Japanese patients with chronic skin disease.

Complementary Therapies in Medicine — Wed, 06 Jun 2007 01:51:38 +0100

CONCLUSIONS: The psychological, physical and psychosomatic symptoms and effects of chronic skin diseases are inextricable. Individualized homeopathic treatment can provoke a good response in patients with chronic skin disease; therefore, the holistic approach used in homeopathy may be a useful strategy alongside conventional treatment. PMID: 17544862 [PubMed - in process] (Source: Complementary Therapies in Medicine)

Adalimumab: Alopecia areata universalis: case report

Reactions — Thu, 18 Jan 2007 00:05:02 +0100

(Source: Reactions)

CORRESPONDENCE: Development of Alopecia Areata Universalis in a Patient Receiving Adalimumab

Archives of Dermatology — Mon, 18 Dec 2006 07:00:00 +0100

(Source: Archives of Dermatology)

Alopecia universalis in down syndrome: Response to therapy

Indian Journal of Dermatology, Venereology and Leprology — Sun, 17 Dec 2006 03:32:06 +0100

Sethuraman Gomathy, Malhotra Amit K, Sharma Vinod KIndian Journal of Dermatology, Venereology and Leprology 2006 72(6):454-455 (Source: Indian Journal of Dermatology, Venereology and Leprology)

Peginterferon/ribavirin: Alopecia universalis: case report

Reactions — Mon, 11 Dec 2006 01:33:03 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Contiguous gene syndrome of holoprosencephaly and hypotrichosis simplex: Association with an 18p11.3 deletion

American Journal of Medical Genetics Part A — Fri, 29 Sep 2006 16:43:02 +0100

We report a patient with a unique combination of features, including microcephaly; mental retardation; poorly developed frontal lobes; hypoplastic pituitary gland; hypothyroidism; alopecia universalis; single maxillary central incisor; taurodontism; median palatal ridge; longitudinally grooved nails; and scoliosis. His unbalanced karyotype was found to be 45,XY,der(15;18)(q10;q10). The constellation of anomalies appears to represent a contiguous gene syndrome caused, at least in part, by deletion of TGIF and the gene responsible for hereditary hypotrichosis simplex. The phenotype of our patient differs other reported patients with del(18p). Possible explanations include (1) the effects of a different deleted region, (2) a positional effect caused by a gene close by, or (3) by interruption ...

What are the possible causes of alopecia universalis in an otherwise fit and healthy 42 year old woman with normal thyroid function tests?

NLH Question Answering Service — Thu, 15 Jun 2006 09:59:16 +0100

You may find it helpful to refer to a US guideline on adult hair disorders [1] which contains a comprehensive section on disorders causing hair loss. The link to this guideline is given in the reference section below. (Source: NLH Question Answering Service)

Disorders of Hair: Alopecia Areata

Medscape Dermatology Headlines — Thu, 08 Jun 2006 06:00:00 +0100

Alopecia areata is typically characterized by patchy hair loss; however, involvement can vary from a single patch on the scalp or elsewhere to total body baldness (alopecia universalis).ACP Medicine Reference (Source: Medscape Dermatology Headlines)